Oxford Biomedica acquires last 10pc stake in US subsidiary
23rd Jun 2025 11:20
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
Read moreOxford Biomedica reports first-half revenue growth
23rd Sep 2024 11:16
(Sharecast News) - Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic advancements in its interim results on Monday.
Read moreOxford Biomedica still expecting small loss after solid first half
8th Aug 2024 12:38
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation Oxford Biomedica reported a strong first-half trading performance in an update on Thursday, with revenue expected to reach £50m.
Read moreOxford Biomedica appoints new finance chief
17th Jul 2024 09:51
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica announced the appointment of Lucinda 'Lucy' Crabtree as its new chief financial officer and a member of the board on Wednesday.
Read moreOxford Biomedica confident as it moves away from vaccine era
29th Apr 2024 08:09
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
Read moreOxford Biomedica shares rise on post-acquisition guidance
5th Mar 2024 16:22
(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.
Read moreDirector dealings: TUI, Oxford Biomedica board members linked to buys
27th Sep 2023 11:24
(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.
Read moreLiberum cuts target price for Oxford Biomedica, saying it still lacks sufficient scale
28th Nov 2022 11:43
(Sharecast News) - Analysts at Liberum cut their target price for shares Oxford Biomedica arguing that the company's pan-vector offering had yet to reach sufficient scale in order to deliver sustainable profitability.
Read moreOxford Biomedica taps Frank Mathias as its new CEO
22nd Nov 2022 09:30
(Sharecast News) - Gene and cell therapy specialist Oxford Biomedica announced the appointment of Dr Frank Mathias as its new chief executive officer and a board director on Tuesday, effective from March.
Read moreOxford Biomedica swings to loss as Covid vaccine winds down
15th Sep 2022 10:27
(Sharecast News) - Oxford Biomedica reported a 21% decrease in its first-half total revenue on Thursday, to £64m.
Read moreOxford Biomedica inks LSA with new US biotech partner
7th Sep 2022 07:42
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck a new licence and supply agreement with an unnamed US partner.
Read moreOxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics
26th Jul 2022 08:44
(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.
Read moreOxford Biomedica signs new Covid vaccine deal with AstraZeneca
1st Jul 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read moreOxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial
14th Jun 2022 09:35
(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.
Read moreOxford Biomedica reports year of solid growth
20th Apr 2022 09:10
(Sharecast News) - Oxford Biomedica reported a 63% improvement in total revenues in its preliminary results on Wednesday, to £142.8m, although its outlook was somewhat less rosy amid a pause in vaccine manufacturing.
Read more